1. News
  2. IRB Barcelona researcher Roger Gomis receives an award for his work on cancer

IRB Barcelona researcher Roger Gomis receives an award for his work on cancer

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab

Roger Gomis, head of the Growth Control and Cancer Metastasis Lab
2 Nov 2018

The Spanish Association of Cancer Research recognizes his work and grants him the ASEICA Young Investigator Award 2018.

The award ceremony will be held in Valencia on 6, 7 and 8 November.

The Spanish Association for Research on Cancer (ASEICA) has announced the winners of the 2018 ASEICA Awards, among them Roger Gomis, head of the Growth Control and Metastasis  lab at IRB Barcelona, who has received the Young Investigator Award in acknowledgement of his work on cancer.

ICREA researcher Roger Gomis leads a multidisciplinary lab devoted to metastasis research at IRB Barcelona. His work focuses on the identification and functional validation of the mechanisms that allow breast and colon cancer to metastasize to clinically relevant sites, and he has published various important articles in recent years.

“These awards aim to acknowledge the magnificent work that Spanish scientists are doing in spite of insufficient resources in the country,” said Carlos Camps, president of ASEICA.

The projects of the awardees will be presented in Valencia on 6,7 and 8 November in a gathering that will serve to disseminate advances in cancer research, present the most recent studies in the field, and showcase the work being undertaken on different types of tumour.

 

More information: http://www.aseica.es/

 

If you want to know more about the research that Roger Gomis lab does, you can watch the Meet Our Scientists Video "Light and credibility": https://www.youtube.com/watch?v
 

 

About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 25 laboratories and seven core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and 32 nationalities. It is located in the Barcelona Science Park. IRB Barcelona forms part of the Barcelona Institute of Science and Technology (BIST) and the “Xarxa de Centres de Recerca de Catalunya” (CERCA).

cancer
metastasis
breast cancer
award

Related content

News

<p>Gloria Pascual, Research Associate at IRB Barcelona. Picture: Fundación Pfizer</p>

Gloria Pascual receives a prize for her research into the relation between fats and metastasis

The Pfizer Foundation has awarded the IRB Barcelona scientist a prize within the “Basic Research” category.

Gloria Pascual, a member of the Stem Cells and Cancer lab, will receive €10,000 to continue her research

<p>Source: Vi per Vida</p>

AT Roca collaborates with the Vi per Vida Foundation with “Cop de Cor”

Nació Digital, the Vinos y Restaurantes magazine and Vinetur, have published an article about the collaboration of AT Roca, a winery in Sant Sadurní d'Anoia, through the fundraising wine "Cop de Cor", which the foundation has been producing since 2015. This project aims to support research into cancer and metastasis conducted at IRB Barcelona and increase public awareness of the value of cancer research.

Link to Nació Digital

<p>Roger Gomis, head of the Growth Control and Cancer Metastasis Lab</p>

More research has to be done into cancer

La Vanguardia has published an opinion article by Roger Gomis, head of the Control of Growth and Cancer Metastasis lab at IRB Barcelona, in the framework of the World Cancer Day. In the article, the researcher gives information about the latest report from the AECC, ASEICA and the la Caixa Foundation. "In recent decades, joint action in prevention, diagnosis, surgery and new therapies has had a notable impact on patient survival, increasing from 20% to 55% today.